The Government of Canada continues to make significant investments in Canada's biomanufacturing and life sciences sector to develop innovative solutions and long-term domestic biomanufacturing ...
From a historic vaccine approval to a $50bn investment reshaping US drug manufacturing, February brought major pharma news to ...
Lenacapavir, a twice yearly injection that prevents HIV transmission, was named the breakthrough medicine of 2024. But ...
Gilead Sciences recently experienced a significant ... The global race is on to secure supply of these critical minerals. Beat the pack to uncover the best rare earth metal stocks of the very ...
Investors with a lot of money to spend have taken a bullish stance on Gilead Sciences GILD. And retail traders should know. We noticed this today when the trades showed up on publicly available ...
Across the recent three months, 14 analysts have shared their insights on Gilead Sciences GILD, expressing a variety of opinions spanning from bullish to bearish. The following table encapsulates ...
Over the twelve months to December 2024, Gilead Sciences recorded an accrual ratio of -0.27. That implies it has very good cash conversion, and that its earnings in the last year actually ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback